{"schema_version":"secwatch.filing_event.v1","accession":"0001655759-24-000113","form_type":"8-K","ticker":"ARVN","cik":"0001655759","company_name":"ARVINAS, INC.","filed_at":"2024-07-30T23:59:59+00:00","discovered_at":"2026-05-14T18:03:13.986289+00:00","generated_at":"2026-05-31T15:19:50.841922+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Arvinas Q2 2024: $1.2B cash, $150M Novartis upfront, VERITAC-2 data 4Q24/1Q25","bullets":["Cash, equivalents, and marketable securities $1.234B as of June 30, 2024; sufficient into 2027.","Revenue $76.5M (+$22M YoY) driven by $45.4M from Novartis ARV-766 license/asset purchase.","R&D expenses $93.7M (-$9.7M YoY); G&A $31.3M (+$5.6M) on higher personnel and professional fees.","VERITAC-2 enrollment on track to complete 4Q24; topline data now expected 4Q24/1Q25.","Novartis deal closed with $150M upfront; potential $1.01B in milestones plus royalties; leadership strengthened (CFO, President R&D, CSO, CBO)."],"urls":{"canonical":"https://secwatch.observer/filing/0001655759-24-000113","json":"https://secwatch.observer/filing/0001655759-24-000113.json","markdown":"https://secwatch.observer/filing/0001655759-24-000113.md","text":"https://secwatch.observer/filing/0001655759-24-000113.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1655759/000165575924000113/0001655759-24-000113-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1655759/000165575924000113/arvn-20240730.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T15:19:50.841922+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}